Martin Shkreli

Shares of KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) rose more than 1,000 percent on Thursday morning, surpassing $14.70 per share. The stock then fell to around $9.50, still up more than 350 percent on Thursday afternoon. The surge was triggered by the announcement that a group of investors (led...

KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) is a monoclonal antibody therapeutics company that traded as a penny stock as recently as this Monday. The company now trades above the $15.00 mark on Wednesday's after-hours session after an SEC disclosure from noted biotech investor Martin Shkreli...

Martin Shkreli, CEO of Turing Pharmaceuticals, hosted a Reddit "Ask Me Anything." Shkreli became "the most hated man on the Internet" after he acquired a drug called Daraprim and raised its price to $750 a pill from $13.50. The top thread featured a discussion with a confirmed doctor who "schooled...

Investors are often fickle figures on Twitter. It doesn't help if these people are invested in a volatile, erratic space such as biotech. Couple that with a niche drug, Daraprim, that treats a very serious disease in Toxoplasmosis (via AIDS) and you have your makings of a public groundswell. After...

Hillary Clinton tweeted that "price gouging" in the specialty drug market is "outrageous." Terry Haines of Evercore ISI commented in a note that there is "almost no chance" of a president legislating drug pricing regulation. An appeal by Democratic candidate to "control" or "gauge" drug pricing...

A butterfly flaps its wings in China and a tsunami devastates Chile. In the biotech world, a finance-themed version of the butterfly effect is unfolding. As reported in the New York Times on Sunday, Turing Pharmaceuticals' Daraprim -- a drug used to treat toxoplasmosis -- saw its price...